[go: up one dir, main page]

CL2008002310A1 - Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad. - Google Patents

Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad.

Info

Publication number
CL2008002310A1
CL2008002310A1 CL2008002310A CL2008002310A CL2008002310A1 CL 2008002310 A1 CL2008002310 A1 CL 2008002310A1 CL 2008002310 A CL2008002310 A CL 2008002310A CL 2008002310 A CL2008002310 A CL 2008002310A CL 2008002310 A1 CL2008002310 A1 CL 2008002310A1
Authority
CL
Chile
Prior art keywords
ht2a
serotonin
dopamine
anxiety
depression
Prior art date
Application number
CL2008002310A
Other languages
English (en)
Inventor
Jaeschke Georg
Maria Rodriguez Sarmiento Rosa
Gobbi Luca
Steward Lucinda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002310A1 publication Critical patent/CL2008002310A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL (I) EN LA QUE R1 Y A TIENEN LOS SIGNIFICADOS DEFINIDOS EN LA DESCRIPCIÓN, COMO MODULADORES DUALES DE LOS RECEPTORES DE LA SEROTONINA 5-HT2A  Y DE LA DOPAMINA D3, SU OBTENCIÓN, LAS COTNPOSJC¡I9NES FARMACÉUTICAS QUE LOS CONTIENEN Y SU UTILIZACIÓN COMO MEDICAMENTOS. LOS COMPUESTOS DE GENERAL FORMULA (I) TIENEN UNA GRAN AFINIDAD CON LOS RECEPTORES DE LA DOPAMINA D3 Y DE LA SEROTONINA (5-HIDROXITRIPTAMLNA; 5-HT) 5-HT2A Y SON EFICACES PARA EL TRATAMIENTO DE TRASTORNOS PSICÓTICOS, ASI COMO OTROS TRASTORNOS, TALES COMO LA DEPRESIÓN Y LA ANSIEDAD, LA DEPENDENCIA DE FÁRMACOS, LAS DEMENCIAS Y LOS DESEQUILIBRIOS DE MEMORIA.<br />  
CL2008002310A 2007-08-09 2008-08-06 Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad. CL2008002310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114119 2007-08-09

Publications (1)

Publication Number Publication Date
CL2008002310A1 true CL2008002310A1 (es) 2009-05-29

Family

ID=39865594

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002310A CL2008002310A1 (es) 2007-08-09 2008-08-06 Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad.

Country Status (16)

Country Link
US (1) US8097637B2 (es)
EP (1) EP2185513B1 (es)
JP (1) JP5296073B2 (es)
KR (1) KR101171467B1 (es)
CN (1) CN101778820B (es)
AR (1) AR067873A1 (es)
AT (1) ATE512137T1 (es)
AU (1) AU2008285729B2 (es)
BR (1) BRPI0814999A2 (es)
CA (1) CA2694057A1 (es)
CL (1) CL2008002310A1 (es)
ES (1) ES2366766T3 (es)
MX (1) MX2010001195A (es)
PE (1) PE20090513A1 (es)
TW (1) TW200914422A (es)
WO (1) WO2009019174A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399447T3 (es) 2006-02-17 2013-04-01 F. Hoffmann-La Roche Ag Derivados benzoil-piperidina como moduladores de 5HT2/D3
RU2480466C2 (ru) * 2007-07-26 2013-04-27 Ф.Хоффманн-Ля Рош Аг Двойные модуляторы 5-ht2a и d3-рецепторов
US8586579B2 (en) 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8921397B2 (en) * 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
WO2013086266A2 (en) * 2011-12-08 2013-06-13 The Board Of Regents Of The University Of Texas System Allosteric modulators of 5-hydroxytryptamine 2c receptor (5-ht2cr)
HRP20200584T1 (hr) 2014-12-12 2020-07-10 Japan Tobacco Inc. Spojevi dihidropirimidin-2-ona i njihova upotreba u medicini
CN117550989B (zh) * 2023-11-14 2024-09-27 泰州精英化成医药科技有限公司 一种反式-2-(4-氨基环己基)乙酸乙酯盐酸盐的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717479B1 (fr) * 1994-03-18 1996-06-07 Pf Medicament Nouvelles 3-(omega-benzoylpipéridino) alcoyl)-4H-Benzopyran-4-ones, leur préparation et leur application en thérapeutique.
HUP0103986A2 (hu) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
AU2002366766A1 (en) * 2001-12-13 2003-07-09 Sumitomo Pharmaceuticals Co., Ltd. Serotonine reuptake inhibitor
ES2399447T3 (es) * 2006-02-17 2013-04-01 F. Hoffmann-La Roche Ag Derivados benzoil-piperidina como moduladores de 5HT2/D3

Also Published As

Publication number Publication date
ATE512137T1 (de) 2011-06-15
AR067873A1 (es) 2009-10-28
AU2008285729A1 (en) 2009-02-12
BRPI0814999A2 (pt) 2015-02-03
CN101778820B (zh) 2012-12-05
PE20090513A1 (es) 2009-04-29
EP2185513A1 (en) 2010-05-19
MX2010001195A (es) 2010-03-01
US20090042943A1 (en) 2009-02-12
CN101778820A (zh) 2010-07-14
EP2185513B1 (en) 2011-06-08
JP2010535735A (ja) 2010-11-25
CA2694057A1 (en) 2009-02-12
WO2009019174A1 (en) 2009-02-12
US8097637B2 (en) 2012-01-17
AU2008285729B2 (en) 2012-11-01
TW200914422A (en) 2009-04-01
ES2366766T3 (es) 2011-10-25
JP5296073B2 (ja) 2013-09-25
KR101171467B1 (ko) 2012-08-07
KR20100029850A (ko) 2010-03-17

Similar Documents

Publication Publication Date Title
CL2008002310A1 (es) Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad.
CR10872A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
GT201000153A (es) Agonistas novedosos de los receptores de glucocorticoides
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
ECSP10010533A (es) Derivados de 4-aminociclohexano sustituido
HN2010001563A (es) Compuestos
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
NI201500106A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
CR9814A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CR20130056A (es) Derivados heterocíclicos fusionados como moduladores s1p
EA201500651A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3